← Thursday 22 Octobernote 6 of 11
Health researchThu 22 Oct 2026 · 6 of 11

Canada's under‑5s largely active and well‑rested, but screen‑time compliance low

Partly verified · 9/10 supported1 cited · 1 min read

Medical Xpress reports that 67% of Canadian children under age 5 met the physical activity recommendation . Medical Xpress reports that 80% of those children met the sleep recommendation . Medical Xpress reports that fewer than half—48%—met screen‑time limits . Medical Xpress reports that only 25% met all three recommendations for activity, sleep and screen time . Medical Xpress reports that the guidelines advise 12–17 hours of sleep for babies under 1 year, 11–14 hours for toddlers 1–2, and 10–13 hours for preschoolers 3–4, plus at least 30 minutes of tummy time for babies and a minimum of 180 minutes of daily physical activity for toddlers and preschoolers .

Why it matters. Medical Xpress notes that the low screen‑time compliance presents a challenge for child‑health efforts targeting sedentary behavior .

Earlier on Health research

Wed 21 Oct 2026Study links autoimmune rheumatic diseases to higher long COVID riskMedical Xpress reports that a retrospective cohort study by Namrata Singh, M.D., and colleagues, published online Oct 14 in Arthritis & Rheumatology, examined long COVID in patients with autoimmune rheumatic diseases (AIRD) using data from the National Clinical Cohort Collaborative. Medical Xpress reports that the study found AIRD patients have an increased risk for long COVID compared with non‑AIRD controls. Medical Xpress reports that higher acute COVID‑19 severity, pulmonary disease, obesity, and exposure to rituximab or glucocorticoids were linked to greater long COVID risk among AIRD patients. Medical Xpress reports that Sjögren syndrome was associated with a higher risk of long COVID in the AIRD cohort.Wed 21 Oct 2026FDA approves Hibsago, first antisense drug for chronic hepatitis BThe U.S. Food and Drug Administration approved Hibsago (bepirovirsen) injection, to be used with existing antiviral therapy, for treating chronic hepatitis B virus infection in certain adults without cirrhosis. Hibsago is the first FDA‑approved antisense oligonucleotide for chronic hepatitis B. Approval is limited to adults without cirrhosis who have been on HBV antiviral therapy for at least six months, have suppressed HBV levels, and have hepatitis B surface antigen levels of 3,000 IU/mL or less, as measured by an FDA‑authorized test. The treatment is intended to give some patients the possibility of maintaining control of the virus after completing chronic HBV therapy.Tue 20 Oct 2026Risk‑taking behavior precedes increased drinking in AUD, study findsMedical Xpress reports that increases in risk‑taking behavior in people with mild to moderate alcohol use disorder precede increases in alcohol consumption, not the reverse. Medical Xpress reports that the study used gamified smartphone‑based decision‑making tasks to predict real‑life drinking changes longitudinally. Medical Xpress reports that the findings were published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Medical Xpress reports that the results suggest potential for future targeted and timely interventions for people with AUD. Medical Xpress reports that AUD is a major contributor to global disability and mortality, and prior cross‑sectional studies linked it to reduced cognitive control and heightened risky decision‑making.
Next · Formula 1How to stream the 2026 United States Grand Prix on F1 TV →